Tag: candidate

French pharmaceutical firm Sanofi on Friday announced the launch of human trials of its second COVID-19 vaccine, with its first still in the testing phase after having fallen behind in development. Sanofi and US company Translate Bio are developing the vaccine based on messenger RNA technology. The phase 1 and 2 trials aim to verify

Researchers from Cleveland Clinic’s Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models. According to new findings published in mBio, the vaccine produced potent neutralizing antibodies among preclinical models and also prevented infection and disease symptoms

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses—including several that distinguish it from other COVID-19 vaccine approaches—according to a preprint deposited in the BioRxiv repository this week. Partial preclinical results had been announced in July and August by

Virologists at the Rega Institute at KU Leuven (Belgium) have developed a vaccine candidate that protects hamsters from infection with the SARS-CoV-2 coronavirus. Theirs is one of the first vaccine candidates that is proven to protect lab animals from infection. The team aims to start clinical trials next Winter. Their findings are pending peer review,

Researchers have modified the protein Nurr1 so that it can enter cells from the outside. Nurr1 deficiency may be one of the causes of Parkinson’s disease. Even though Nurr1 has been discussed as a potential target for the treatment of Parkinson’s disease, it is unusable in its normal form, as it cannot penetrate cells. A